Induction of proliferative lesions of the uterus, testes, and liver in Swiss mice given repeated injections of sodium arsenate: Possible estrogenic mode of action

Toxicology and Applied Pharmacology

Volumn 166, Issue 1, 2000, Pages 24-35

  Waalkes, Michael P ^a   Keefer, Larry K ^b   Diwan, Bhalchandra A ^c  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c SAIC FREDERICK INC   (United States)

Author keywords

Arsenic; Liver; Mice; Proliferative lesions; Testes; Uterus

Indexed keywords

3 NITROTYROSINE; ARSENATE SODIUM; CYCLIN D1; CYCLINE; ESTROGEN RECEPTOR; GENE PRODUCT; NITRIC OXIDE SYNTHASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CARCINOGENESIS; CELL CYCLE G1 PHASE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; ENVIRONMENTAL EXPOSURE; ESTROGEN ACTIVITY; FEMALE; HISTOPATHOLOGY; KERATODERMA; LEYDIG CELL; LIVER HYPERPLASIA; MALE; MOUSE; NONHUMAN; RECEPTOR UPREGULATION; SEX DIFFERENCE; SURVIVAL RATE; TESTIS TUMOR;

ANIMALIA; RODENTIA;

EID: 0034235635     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1006/taap.2000.8963     Document Type: Article

References (57)

1. Agency for Toxic Substances and Disease Registry (ATSDR), 1999, Top 20 Hazardous Substances: ATSDR/EPA Priority List for 1999, (, http://atsdr1.atsdr.cdc.gov:8080/cxcx3.html , ).
2. Ambs S., Merriam W. G., Bennett W. P., Felley-Bosco E., Ogunfusika M. O., Oser S. M., Klein S., Shields P. G., Billiar T. R., Harris C. C. Frequent nitric oxide synthase-2 expression in human colon adenomas: Implication for tumor angiogenesis and colon cancer progression. Cancer Res. 58:1998;334-341.
3. Barton M. C., Shapiro D. J. Transient administration of estradiol-17β establishes an autoregulatory loop permanently inducing estrogen receptor mRNA. Proc. Natl. Acad. Sci. USA. 85:1988;7119-7123.
4. Beato M., Herrlich P., Schütz G. Steroid hormone receptors: Many actors in search of a plot. Cell. 83:1995;851-857.
5. Bosland M. C. Male reproductive system. Waalkes M. P., Ward J. M. Target Organ Toxicology Series: Carcinogenesis. 1994;339-402 Raven Press, New York.
6. Bosland M. C. Hormonal factors in carcinogenesis of the prostate and testis in humans and in animal models. Prog. Clin. Biol. Res. 394:1996;309-352.
7. Buckley M. F., Sweeney K. J. E., Hamilton J. A., Sini R. L., Manning D. L., Nicholson R. I., deFazio A., Watts C. K. W., Musgrove E. A., Sutherland R. L. Expression and amplification of cyclin genes in human breast cancer. Oncogene. 8:1993;2127-2133.
8. Chwalisz K., Garfield R. E. Role of nitric oxide in the uterus and cervix: Implications for the management of labor. J. Perinat. Med. 26:1998;448-457.
9. Cobbs C. S., Brenman J. E., Aldape K. D., Bredt D. S., Israel M. A. Expression of nitric oxide synthase in human central nervous system tumors. Cancer Res. 55:1995;727-730.
10. Crum C. P. Female genital tract. Cotran R. S., Kumar V., Robbins S. L. Pathologic Basis of Disease. 1994;1033-1088 W.B. Saunders, Philadelphia.
11. Davis D. L., Bradlow H. L. Can environmental estrogens cause breast cancer? Sci. Am. 273:1995;166-172.
12. Diwan B. A., Anderson L. M., Ward J. M. Proliferative lesions of oviduct and uterus in CD-1 mice exposed prenatally to tamoxifen. Carcinogenesis. 18:1997;2009-2014.
13. Diwan B. A., Meier H. Carcinogenic effects of a single dose of diethylnitrosamine in three unrelated strains of mice: Genetic dependence of the induced tumor types and incidence. Cancer Lett. 1:1976;249-253.
14. Felley-Bosco E. Role of nitric oxide in genotoxicity: Implication for carcinogenesis. Cancer Metastasis Rev. 17:1998;25-37.
15. Gallo O., Masini E., Morbidelli L., Franchi A., Fini-Storchi I., Vergari W. A., Ziche M. Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer. J. Natl. Cancer Inst. 90:1998;587-596.
16. Germolec D. R., Spalding J., Yu H.-S., Chen G. S., Simeonova P. P., Humble M. C., Bruccoleri A., Boorman G. A., Foley J. F., Yoshida T., Luster M. I. Arsenic enhancement of skin neoplasia by chronic stimulation of growth factors. Am. J. Pathol. 153:1998;1775-1785.
17. Goering P. L., Aposhian H. V., Mass M. J., Cebrián M., Beck B. D., Waalkes M. P. The enigma of arsenic carcinogenesis: Role of metabolism. Toxicol. Sci. 49:1999;5-14.
18. Healy S. M., Casarez E. A., Ayala-Fierro F., Aposhian H. V. Enzymatic methylation of arsenic compounds. V. Arsenite methyltransferase activity in tissues of mice. Toxicol. Appl. Pharmacol. 148:1998;65-70.
19. Huseby R. A. Estrogen-induced Leydig cell tumor in the mouse: A model system for the study of carcinogenesis and hormone dependency. J. Toxicol. Environ. Health. 1976;177-192.
20. IARC (International Agency for Research on Cancer), 1980. In, IARC Monographs on the Evaluation of Carcinogenic Risks of Chemicals to Humans: Some Metals and Metallic Compounds, Vol, 23, World Health Organization, IARC, Lyon.
21. IARC, 1987. In, IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Humans: Overall Evaluations of Carcinogenicity: An Updating of IARC Monographs 1 to 42, World Health Organization, IARC, Lyon.
22. Ignar-Trowbridge D. M., Nelson K. G., Bidwell M. C., Curtis S. W., Washburn T. F., McLachlan J. A., Korach K. S. Coupling of dual signaling pathways: Epidermal growth factor action involves the estrogen receptor. Proc. Natl. Acad. Sci. USA. 89:1992;4658-4662.
23. Johnson L. D. Lesions of the female genital system caused by diethylstilbestrol in humans, subhuman primates, and mice. Jones T. C., Mohr U., Hunt R. D. Genital System, Monographs on Pathology of Laboratory Animals. 1987;84-109 Springer Verlag, Berlin.
24. Korach K. S., Davis V. L., Curtis S. W., Bocchinfuso W. B. Xenoestrogens and estrogen receptor action. Thomas J. A., Colby H. D. Endocrine Toxicology. 1997;181-211 Taylor & Francis, Washington.
25. Kotsanis N., Iliopoulou-Georgudaki J. Arsenic induced liver hyperplasia and kidney fibrosis in rainbow trout (Oncorhynchus mykiss) by microinjection technique: A sensitive animal bioassay for environmental metal-toxicity. Bull. Environ. Contam. Toxicol. 62:1999;169-178.
26. Lala P. K. Significance of nitric oxide in carcinogenesis, tumor progression and cancer therapy. Cancer Metastasis Rev. 17:1998;1-6.
27. Liu, J, Liu, Y, Goyer, R. A, Achanzar, W, and, Waalkes, M. P. 2000, Metallothionein-I/II null mice are more sensitive than wild-type mice to the hepatotoxic and nephrotoxic effects of chronic oral or injected inorganic arsenicals. In press.
28. MacMillan-Crow L. A., Thompson J. A. Immunoprecipitation of nitrotyrosine-containing proteins. Methods Enzymol. 301:1999;135-145.
29. Metzler M., Degen G. H. Sex hormones and neoplasia: Liver tumors in rodents. Arch. Toxicol. 1987;251-263.
30. Moolgavkar S. H. Hormones and multistage carcinogenesis. Cancer Surv. 5:1986;635-648.
31. Musgrove E. A., Sutherland R. L. Cell cycle control by steroid hormones. Semin. Cancer Biol. 5:1994;381-389.
32. Nagaoka T., Takeuchi M., Onodera H., Matsushima Y., Ando-Lu J., Maekawa A. Sequential observation of spontaneous endometrial adenocarcinoma development in Donryu rats. Toxicol. Pathol. 22:1994;261-269.
33. National Research Council (NRC), 1999, National Research Council Report: Arsenic in the Drinking Water, National Academy Press, Washington, DC.
34. Newbold R. Cellular and molecular effects of developmental exposure to diethylstilbestrol: Implications for other environmental estrogens. Environ. Health Perspect. 103:1995;83-87.
35. Newbold R. R., Bullock B. C., McLachlan J. A. Adenocarcinoma of the rete testis: Diethylstilbestrol-induced lesions of the mouse rete testis. Am. J. Pathol. 125:1986;625-628.
36. Newbold R. R., Bullock B. C., McLachlan J. A. Testicular tumors in mice exposed in utero to diethylstilbestrol. J. Urol. 138:1987;1446-1450.
37. Osswald H., Goerttler K. Arsenic-induced leucoses in mice after diaplacental and postnatal application. Verh. Dtsch. Ges. Pathol. 55:1971;289-293.
38. (R)-1 HaM-ICR mice. J. Natl. Cancer Inst. 46:1971;1045-1065.
39. Persson I., Weiderpass E., Bergkvist L., Bergström R., Schairer C. Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement. Cancer Causes Control. 10:1999;253-260.
40. Rao V. S. N., Chaves M. C., Ribeiro R. A. Nitric oxide synthase inhibition and the uterotrophic response to oestrogen in immature rats. J. Reprod. Fertil. 105:1995;303-306.
41. Schuppler J., Günzel P. Liver tumors and steroid hormones in rats and mice. Arch. Toxicol. 1979;181-195.
42. Sherr C. J. Mammalian G1 cyclins. Cell. 73:1993;1059-1065.
43. Sherr C. J. G1 phase progression: Cycling on cue. Cell. 79:1994;551-555.
44. Shukla J. P., Pandey K. Impaired ovarian functions in arsenic-treated freshwater fish, Colisa fasciatus (Bl. and Sch.). Toxicol. Lett. 20:1984;1-3.
45. Sicinski P., Donaher J. L., Parker S. B., Li T., Fazeli A., Gardner H., Haslam S. Z., Bronson R. T., Elledge S. J., Weinberg R. A. Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell. 82:1995;621-630.
46. Simons S. S. Jr., Chakraborti P. K., Cavanaugh A. H. Arsenite and cadmium(II) as probes of glucocorticoid receptor structure and function. J. Biol. Chem. 265:1990;1938-1945.
47. Takahashi M., Fukuda K., Ohata K., Sugimura T., Wakabayashi K. Increased expression of inducible and endothelial constitutive nitric oxide synthases in rat colon tumors induced by azoxymethane. Cancer Res. 57:1997;1233-1237.
48. Thomas J. A. Actions of chemicals and other factors on Leydig cell growth and proliferation. Thomas J. A., Colby H. D. Endrocrine Toxicology. 1997;245-256 Taylor & Francis, Washington.
49. Thomsen L. L., Lawton F. G., Knowles R. G., Beesley J. E., Riveros-Moreno V., Moncada S. Nitric oxide synthase activity in human gynecological cancer. Cancer Res. 54:1994;1352-1354.
50. Thomsen L. L., Miles D. W., Happerfield L., Bobrow L. G., Knowles R. G., Moncada S. Nitric oxide synthase activity in human breast cancer. Br. J. Cancer. 72:1995;41-44.
51. Waalkes M. P., Rehm S., Devor D. E. The effects of continuous testosterone exposure on spontaneous and cadmium-induced tumors in the male Fischer (F344/NCr) rat: Loss of testicular response. Toxicol. Appl. Pharmacol. 142:1997;40-46.
52. Wei M., Wanibuchi H., Yamamoto S., Li W., Fukushima S. Urinary bladder carcinogenicity of dimethylarsinic acid in male F344 rats. Carcinogenesis. 20:1999;1873-1876.
53. Weiderpass E., Adami H.-O., Baron J. A., Magnusson C., Bergström R., Lindgren A., Correia N., Persson I. Risk of endometrial cancer following estrogen replacement with and without progestins. J. Natl. Cancer Inst. 91:1999;1131-1137.
54. Wink D. A., Mitchell J. B. Chemical biology of nitric oxide: Insights into regulatory, cytotoxic, and cytoprotective mechanisms of nitric oxide. Free Radic. Biol. Med. 25:1998;434-456.
55. Wink D. A., Vodovotz Y., Laval J., Laval F., Dewhirst M. W., Mitchell J. B. The multifaceted roles of nitric oxide in cancer. Carcinogenesis. 19:1998;711-721.
56. Yamamoto S., Wanibuchi H., Hori T., Yano Y., Matsui-Yuasa I., Otani S., Chen H., Yoshida K., Kuroda K., Endo G., Fukushima S. Possible carcinogenic potential of dimethylarsinic acid as assessed in rat in vivo models: A review. Mutat. Res. 386:1997;353-361.
57. Zava D. T., Blen M., Duwe G. Estrogenic activity of natural and synthetic estrogens in human breast cancer cells in culture. Environ. Health Perspect. 105:1997;637-645.